Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Size, Share, Trends, Growth, Consumption, Revenue, Company Analysis and Forecast 2020-2027

Published Date : Nov 2020 | No. of Pages : 200 Pages | Category : Healthcare

The global ornithine transcarbamylase (OTC) deficiency treatment market size surpassed US$ 600 Mn in 2019 and to reach valuation US$ 856 million by 2027 with a CAGR of 4% from 2020 to 2027.

Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by partial or complete lack of the enzyme ornithine transcarbamylase (OTC). OTC is one of six enzymes that play a role in the breakdown and removal of nitrogen in the body, a process known as urea cycle. Ammonia-scavenging drugs have been utilized in the treatment of urea cycle disorders. Benzoate and Glycerol/Sodium Phenyl Butyrate (NaPB) target liver-nitrogen metabolism by offering an alternative pathway for nitrogen disposal through the urinary excretion of hippurate and phenylacetylglutamine. A combination of a high biological value natural protein, an essential amino acid formula and a calorie supplement without protein and essential amino acids supplements may also be employed for the treatment of ornithine transcarbamylase deficiency. 

North America dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to dominate the global market, in terms of revenue, during the forecast period.

Rise in Prevalence of Ornithine Transcarbamylase (OTC) Deficiency and Development of New Therapies to Drive Global Market

The surge in the number of patients with ornithine transcarbamylase (OTC) deficiency is likely fuel the global ornithine transcarbamylase (OTC) deficiency treatment market. The development of new therapies for ornithine transcarbamylase (OTC) deficiency treatment in the near future and favorable reimbursement policies for OTC deficiency treatment coupled with various patient assistance programs provided by several international and regional organizations are major factors driving the global ornithine transcarbamylase (OTC) deficiency treatment market.

For instance, in January 2020, The Assistance Fund (TAF), an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new financial assistance program for people living with urea cycle disorders. Formulation modification for better patient compliance is also a key factor driving the global ornithine transcarbamylase (OTC) deficiency treatment market.

Ravicti to Dominate Global Market

Based on product, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into Buphenyl, Ravicti, Ammonul, dietary supplements, and others. The Ravicti segment accounted for a major share of the global market in 2019 due to higher efficacy and cost of drug, and better patient compliance, which contributes toward higher revenues. The Buphenyl segment followed the Raviciti segment, in terms of share of the global market, in 2019, owing to pipeline products with improved patient compliance and lesser cost to patients.

Oral a Preferred Route of Administration

In terms of route of administration, the global ornithine transcarbamylase (OTC) deficiency treatment market has been bifurcated into oral and intravenous. The oral segment dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to maintain its dominant share by 2030. Oral is also a highly lucrative segment. It is projected to expand at a notable CAGR during the forecast period, owing to patient preference for oral route and convenience offered by the oral route, approval & launch of oral medication, availability of a large number of products that can be administered through oral route, and new products with improvement in formulation modification for taste masking.

Hospital Pharmacies to be Key Distribution Channel

In terms of distribution channel, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for a major share of the market in 2019 due to higher number of prescriptions filled at these hospital pharmacies, favorable reimbursement scenario, strong supply chain management, and various patient assistance programs run by pharmaceutical companies.

North America to Dominate Global Market

In terms of region, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, owing to a rise in the total number of reported cases of ornithine transcarbamylase (OTC) deficiency, favorable reimbursement policies, presence of major companies, various clinical studies in the region for urea cycle disorder, and better screening approaches for rare diseases. For instance, according to the U.S. National Library of Medicine, prevalence of ornithine transcarbamylase deficiency have ranged from 1 in 14,000 to 1 in 77,000 people in the U.S. The market in Asia Pacific is projected to expand at a higher CAGR during the forecast period, owing to increase in awareness about ornithine transcarbamylase (OTC) deficiency and other urea cycle disorders, surge in screening of patients for the diagnosis of ornithine transcarbamylase (OTC) deficiency, increase in distribution tie-ups between major companies, and rise in investments by major companies in the region.

Competition Landscape

The global ornithine transcarbamylase (OTC) deficiency treatment market is fragmented in terms of the number of players, with entry of several new players. Key players in the global market include Abbott, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics plc, Nestlé, Bausch Health Companies, Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc., and Acer Therapeutics. Mergers, acquisitions & strategic collaborations, distribution tie-ups, increased research & development expenditure, and new product launches are major strategies adopted by companies in the global ornithine transcarbamylase (OTC) deficiency treatment market.

Market Segmentation

By Product

    • Buphenyl
    • Ravicti
    • Ammonul
    • Dietary Supplements
    • Others

By Route of Administration

    • Oral
    • Intravenous

By Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Scope of the Report

VRR’s report on the global ornithine transcarbamylase (OTC) deficiency treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall market revenue of the global ornithine transcarbamylase (OTC) deficiency treatment market for the period 2018-2030, considering 2020 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global ornithine transcarbamylase (OTC) deficiency treatment market for the forecast period.

The report has been prepared after extensive primary and secondary research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global ornithine transcarbamylase (OTC) deficiency treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global ornithine transcarbamylase (OTC) deficiency treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global ornithine transcarbamylase (OTC) deficiency treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global ornithine transcarbamylase (OTC) deficiency treatment market.

The report delves into the competitive landscape of the global ornithine transcarbamylase (OTC) deficiency treatment market. Key players operating in the global ornithine transcarbamylase (OTC) deficiency treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global ornithine transcarbamylase (OTC) deficiency treatment market that have been profiled in this report.

Key Questions Answered

  • What is the sales/revenue generated by each product, route of administration, and distribution channel segment of the global ornithine transcarbamylase (OTC) deficiency treatment market across all regions during the forecast period?
  • What are the opportunities in the global ornithine transcarbamylase (OTC) deficiency treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is likely to expand at the fastest CAGR during the forecast period?
  • Which ornithine transcarbamylase (OTC) deficiency treatment segments are expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the market share or position of different companies operating in the global market in 2019?

Research Objectives and Research Approach

The comprehensive report on the global ornithine transcarbamylase (OTC) deficiency treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, disease prevalence in key countries, Overview of Diagnostics Approach for OTC Deficiency, standard guidelines for approval of drugs, and impact of COVID-19 in global ornithine transcarbamylase (OTC) deficiency treatment market have been provided.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global ornithine transcarbamylase (OTC) deficiency treatment market in terms of product, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ornithine transcarbamylase (OTC) deficiency treatment market.


Featured Research Reports

  • Featured Research Reports

    Orthopedic Soft Tissue Repair Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Coagulation Analyzer Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Biological Implants Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Automated Dispensing Machines Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Neurodiagnostics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...